The cost-effectiveness of treating chronic hepatitis C

Kenneth M. Shermock, Mary E. Temple, Zobair M. Younossi

Research output: Contribution to journalReview articlepeer-review

Abstract

The hepatitis C virus (HCV) is a blood-borne virus that can cause significant morbidity and mortality. Treatment of HCV infection is limited to interferon (IFN), either as monotherapy or in combination with ribavirin. In this article, the pharmacoeconomics of IFN-based therapy for HCV infection is reviewed. Most pharmaco-economic analyses of these agents have used a computer modeling technique called decision analytic modeling. When taken as a whole, these analyses suggest that treating HCV infection with a combination regimen of IFN and ribavirin is the most cost-effective treatment strategy. As new modalities for treating chronic HCV infection are being approved, such as pegylated IFN and ribavirin combinations, it is important to evaluate not only their safety and efficacy but also their cost-effectiveness, and to determine their total impact on patients' health and the health care system.

Original languageEnglish (US)
Pages (from-to)34-40
Number of pages7
JournalDrug Benefit Trends
Volume14
Issue numberSUPPL. A
StatePublished - Jan 1 2002
Externally publishedYes

Keywords

  • Cost-effectiveness
  • Hepatitis C virus
  • Interferon-α
  • Ribavirin

ASJC Scopus subject areas

  • Health Policy
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'The cost-effectiveness of treating chronic hepatitis C'. Together they form a unique fingerprint.

Cite this